Objective: To report a case of typhoid fever contracted in Portugal in 1994 due to a Salmonella typhi isolate which had reduced susceptibility t o fluoroquinolone (MIC 1 mg/L of ciprofloxacin) and high level resistance t o nalidixic acid (MIC 256 mg/L).
I NTRODU CTI 0 N
Spread of multiresistant Salmonella typhi has been reported frequently over the past few years [l-41, but these strains have responded well to fluoroquinolone therapy which has become a treatment of choice for typhoid fever [S-71. More recently, multiresistant S. typhi strains, also resistant to fluoroquinolones, have been isolated in Asia (India, Bengladesh, Pakistan, Nepal) [8, 9] . It has been reported that fluoroquinolone resistance in these strains is associated with a mutation in the gyrA gene [lo] . We report here a case of typhoid fever contracted in Europe (Portugal) and caused by a fluoroquinolone resistant strain of S. typhi (strain FQ1).
An 18-year-old female patient was admitted to our institution in early September 1994 with abdominal pain and fever. She had been in good health until a few days before admission and had no history of recent antibiotic treatment. Ten days after a journey to northern Portugal, she suffered from headache, nausea and giddiness, developed fever (39 " C ) and abdominal pain and was hospitalized for further investigation.
O n admission, her blood pressure was normal and her abdomen was clinically and echographically normal (no splenomegaly). The white blood cell count was 5 . 5~ 10y/L (72% polymorphs), the hematocrit 37.8%) and the platelet count 134x109/L. Liver function tests showed moderate cellular damage (serum aspartate aminotransferase 72 U/L; alkaline aminotransferase 53 U/L) while the bilirubin, creatinine and alkaline phosphatases were normal. HIV and hepatitis I3 and C serologic tests were negative. Blood cultures [6] and stool samples grew S. typhi, and the anti-H-agglutinin titer was 1/200. O n the day of admission, the patient was given amoxicillin (1 g, four times daily, IV), replaced by cefiriaxone (4 g once daily, IV) afier isolation of S. typhi.
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Apyrexia and negative stool culture were obtained after 5 days; ceftriaxone was replaced by amoxycillin (1 g twice daily, orally, for 10 days), and the patient was discharged.
METHODS

Bacterial characterization
The clinical isolates were identified as S. typhi by standard biochemical tests performed on the Api 20E system (API bioM&ieux, Marcy-I'Etoile, France) and serotyped by slide agglutination using Salmonella antiserum (Diagnostics Pasteur, France). Phage type was determined by the French Reference Center for Salmonella and Shigella (Institut Pasteur, Paris, France).
Susceptibility testing
Antibiotic susceptibility was tested by a disk diffusion method on Mueller-Hinton (MH) agar (Diagnostics Pasteur, France). Minimal inhibitory concentrations (MICs) of fluoroquinolones (pefloxacin, ciprofloxacin and nalidixic acid) were determined by an agar plate dilution method performed on M H agar (Diagnostics Pasteur, France), with an inoculum of lo4 CFU per spot and incubation at 37°C for 18 h.
Molecular studies of reduced susceptibility to fluoroquinolones
The nucleotide sequences of a section of the gyrA gene of the clinical strain (FQ1) and a ciprofloxacin-sensitive strain called FQ2 used as a sensitive control were determined.
Chromosomal DNA was prepared as described by Sambrook et a1 [Ill.
Plasniid DNA was prepared by the alkaline lysis method of Birnboim and Doly [12] . This plasmid, called pJSWl0l (5.5 kb), is derived from pUC19 by ligation at the BamHI and SalI sites of the wild-type gyrA gene [ 131. Plasmid DNA was introduced into the FQ1 strain by a transformation procedure with CaC12 [14] . This procedure used competent cells suspended in an ice-cold solution of CaC12 (50 mM). After mixing 200 pL of competent cells and 10-200 ng of DNA in a volume of 50 pL, the Eppendorf tubes were stored on ice for 30 min and placed in a 42OC waterbath for 2 m i n (heat shock). The cells were then diluted in 1 mL of prewarmed (37°C) M H broth and incubated for 60 min at 37OC with gentle agitation. A 200-pL volume of the cells was plated and transformants were selected on Luria Bertani (LB) agar containing ampicillin at 100 pg/mL.
Chromosomal DNA was prepared from one colony of an overnight culture on brain-heart infusion (BHI) agar diluted into 1 mL of sterilized water and boiled for 10 min. A 219-bp fragment from S. typhi was amplified by polymerase chain reaction (PCR) using two oligonucleotides, 5'-TACTTTACGCCAGA-3' and 5'-TCCGTATAACGCATTGCC-3', corresponding to nucleotides f 3 1 to f 4 5 and f 2 4 0 to 259 for forward and reverse reactions, respectively. These primers were synthesized with reference to the quinolone resistance-determining region (QRDR) of S. typhimurium [ 151. Oligonucleotides were synthesized by Eurogentec (Angers, France). Reactions were performed in a DNA thermal cycler (PHC2, Techne, Paris, France): 30 cycles of 1 nlin of denaturation at 94"C, 1 min of annealing at 50°C and 1 min of extension at 72"C, followed by a final extension step at 72°C for 5 min. Amplified P C R fragments isolated from 1% agarose gel were purified by using QIA quick gel extraction (Qiagen, Hilden, Germany) and sequenced with the Promega P C R Sequencing Kit (Promega) according to the manufacturer's recommendation.
RESULTS
AU the isolates were susceptible to ampicillin, cephalosporins, chloramphenicol, trimethoprim, sulfonamides, tetracycline and aminoglycosides. These strains were resistant to nalidixic acid and had reduced susceptibility to fluoroquinolones. The MIC of nalidixic acid was 2 2 5 6 mg/L and the MICs of pefloxacin and ciprofloxacin were 2 and 1 mg/L, respectively.
An isolate of S. typhi from blood culture, referred to as FQ1 of lysotype A, was used for further studies.
Transformation of S. typhi F Q l with plasmid carrying the wild-type gyrA gene resulted in restoration of susceptibility to nalidixic acid, pefloxacin and ciprofloxacin, with MICs, respectively, of 1, 0.06 and 0.007 pg/mL indicating that S. typlzi FQ1 had a mutation in gyrA.
P C K products (as illustrated in Figure 1 ) from the ciprofloxacin-resistant isolate FQ1 from the patient and the ciprofloxacin-sensitive strain FQ2, produced as described above, were sequenced and found to show two mutations: a C+T transition at the position equivalent to nucleotide 248 of gyrA, resulting in a Ser83-+Phe substitution; and a silent mutation at the position equivalent to nucleotide 354 (A+C).
DISCUSSION
Typhoid fever is a serious infection, still observed in many countries. Treatment by fluoroquinolones has been shown to be effective and well tolerated in many clinical trials [7] . Fluoroquinolones represent a treatment of choice, because many S. typhi isolates are multiply resistant to several unrelated drugs, including ampicillin, chloramphenicol and trimethoprim 171.
Additionally, fluoroquinolones have been successfully used for the eradication of long-term gastrointestinal carriage 171.
Kecent reports, however, have shown that some multiresistant isolates do not respond to fluoroquinolone therapy 116-181. Many of these strains had reduced susceptibility to fluoroquinolones (MIC of ciprofloxacin 0.25 pg/mL). A mutation at serine-83 in the GyrA protein has been shown in several strains to confer decreased susceptibility to fluoroquinolones. In most but not all strains, high-level resistance to nalidixic acid was observed, and it has been reported that some of these S. typlzi isolates did not respond to ciprofloxacin therapy More recently, two strains of S. typhi less susceptible to fluoroquinolones, acquired in western Europe, have been isolated. The first strain was described by Le Lostec et a1 [19] and the second is described in this paper (strain FQ1). Both strains were isolated from patients with a history of recent travel in northern Portugal. Both strains, unlike the Asian strains, were susceptible to ampicillin, chloramphenicol and trimethoprini. MICs of ciprofloxacin were 0.12 and 1 pg/nlL, respectively, and both belonged to lysotype A. Initial treatment of the first patient with fluoroquinolone was ineffective, with fever and positive blood culture persisting after 48 h; this patient was successfully treated with amoxycillin. Our patient was initially given anioxycillin, and then ceftriaxone, but no fluoroquinolone was used. Complementation tests with a wild-type allele of strain FQ1 showed that a mutation had occurred in the gyrA gene of this clinical isolate, with a serine to phenylalanine substitution at position 83, similar to that described in Asian strains [lo] .
Problems arising from S. typhi strains with reduced susceptibility to fluoroquinolones must be kept in mind by clinicians and microbiologists, since failures of treatment with ciprofloxacin have been reported [16] [17] [18] [19] Furthermore, the number of such strains with low-level resistance to fluoroquinolones is underestimated, since, in the usual susceptibility tests with the breakpoints presently accepted worldwide, such strains are categorized as susceptible. Therefore to detect this low level of resistance, we would suggest that all S. typhi isolates should be tested with nalidixic acid 30 pg disk as well as with ciprofloxacin. Strains resistant to nalidixic acid should be reported to the clinician, and the MIC of ciprofloxacin measured.
